STOCK TITAN

Harmony Biosciences Holdings Inc - HRMY STOCK NEWS

Welcome to our dedicated news page for Harmony Biosciences Holdings (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harmony Biosciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harmony Biosciences Holdings's position in the market.

Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
conferences
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) ranks 25th on the Deloitte Technology Fast 500™, with a remarkable revenue growth of 7,204% from fiscal year 2019 to 2022. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases. Jeffrey M. Dayno, MD, President and CEO, expressed honor in being recognized as one of the fastest-growing companies in North America and looks forward to future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
HRMY: Harmony Biosciences Appoints Peter Anastasiou to Board of Directors, Bringing Expertise in CNS and Business Development. The appointment aims to support growth priorities and develop new treatment options for rare neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
management
Rhea-AI Summary
Harmony Biosciences reported net revenue of $160.3 million for Q3 2023, a 37% increase YoY. The average number of patients on WAKIX increased by approximately 350 sequentially to around 5,800. The company acquired Zynerba Pharmaceuticals and repurchased 1.4 million shares of common stock for $50 million. Harmony also announced a new $200 million share repurchase program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.43%
Tags
earnings
-
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. has selected new nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, providing funding support for initiatives addressing sleep disorders and rare neurological diseases. The initiatives aim to enhance care, education, and awareness for patients, caregivers, and professionals. The company is dedicated to supporting transformation within these communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary
Harmony Biosciences to report Q3 2023 financial results on October 31, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
conferences earnings
Rhea-AI Summary
Harmony Biosciences announces positive results from INTUNE study in patients with idiopathic hypersomnia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.25%
Tags
clinical trial
-
Rhea-AI Summary
Harmony Biosciences completes acquisition of Zynerba Pharmaceuticals, expanding its portfolio with Zygel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
acquisition
-
Rhea-AI Summary
Harmony Biosciences presents new data on pitolisant for the treatment of excessive daytime sleepiness in Prader-Willi syndrome
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
clinical trial
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. extends tender offer for Zynerba Pharmaceuticals, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
acquisition
Harmony Biosciences Holdings Inc

Nasdaq:HRMY

HRMY Rankings

HRMY Stock Data

1.91B
34.80M
19.38%
90.02%
10.72%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Plymouth Meeting

About HRMY

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.